• Privacy Analytics

  Participated · Equity · Jul 2014

  Privacy Analytics offers PARAT, an enterprise software suite that automates anonymization of structured and unstructured data to safeguard and enable secondary uses. PARAT sets re-identification risk thresholds based on situational and intended use and applies those thresholds to database tables, text and other document formats in accordance with HIPAA and other regulatory requirements. The software yields high-quality individual-level data for research, quality improvement, public health, payment and testing while protecting personal information. Customers include half of Fortune 50 healthcare companies and research organizations such as the Center for Clinical Excellence at Mount Sinai and the BORN Registry. Founded in 2007 and incubated at the University of Ottawa from research at the Children’s Hospital of Eastern Ontario’s Research Institute, the company’s PARAT technology is patented and peer-reviewed. The company plans to use new funding to expand sales and marketing and to bolster development of the PARAT product line. Privacy Analytics provides solutions that enable secondary users to access high-quality, de-identified data suitable for the most complex analytics while meeting legal, privacy and compliance regulations. Its customers include commercial organizations in healthcare, consumer and financial services, research organizations, and government departments. The company's technology facilitates research and analysis, can eliminate the need to obtain individual consent for certain secondary data uses, and reduces the effort and cost to comply with governmental regulations and guidelines. Privacy Analytics is led by founder and CEO Dr. Khaled El Emam and is based in Ottawa, Ontario, Canada. The company recently closed a venture capital funding round of undisclosed size backed by the BDC IT Venture Fund and the Capital Angel Network. It intends to use the capital to ramp up sales and marketing efforts. Privacy Analytics develops the Privacy Analytics Risk Assessment Tool (PARAT), a Windows-based software platform that helps hospitals and patient registries disclose detailed disease and treatment data while protecting individual privacy. PARAT is compatible with multiple databases, including Oracle and Microsoft SQL Server, and is currently being used by hospitals and patient registries in Canada. The company has received an equity investment from The Ontario Institute for Cancer Research (OICR) through its Intellectual Property Development and Commercialization Program. The amount of the investment was not disclosed. OICR's funding will be used to extend PARAT's functionality and to support marketing and sales of the improved product into new markets. The OICR program provides seed funding for late-stage academic projects that meet specific market-oriented criteria.

• DVS Sciences

  Participated · Series A · Jul 2011

  DVS Sciences produces the CyTOF mass cytometer and a suite of MAXPAR reagents, a combined solution for quantitative single-cell analysis that can simultaneously identify up to 100 biomarkers. The CyTOF–MAXPAR platform eliminates spectral overlap issues of conventional flow cytometry and is positioned for applications in biomarker discovery, drug discovery, clinical trials and personalized medicine. The company reports CyTOF systems installed in leading laboratories across the U.S., Canada and Asia. DVS Sciences is a spin-off from the University of Toronto and maintains an R&D and manufacturing facility near Toronto with global headquarters in Sunnyvale, California. The firm plans to accelerate commercial manufacturing scale-up to broaden commercialization of its instrumentation and reagents. The recent Series A financing will support that commercial expansion and continued product deployment.

No current team members are available.